LegalCaseDocs.com
shopping cart  
  |     
Search
 

 
New Visitors


 VeriSign Secure Site

 Get Adobe Reader

YVETTE VEIDEMAN v ICN PHARMACEUTICALS INC Click to find out why . . .



Keywords & Phrases
CaseNo: YVVIPI209306, CourtName: MISC 3, Plaintiff: YVETTE VEIDEMAN, State: CA California, UniqueCaseRef: LCD>YVVIPI209306, Icn, Stock, Report, Violations, Royalties, Investors, Revenue, Sales, Shares, Fasb Statement, Enterprise, Act, Schering-plough, Pharmaceuticals, Securities, Shareholder, Receivables, Analysts, Management, Resources, Directors, Ribapharm, Control, Expectations, Eps, Gaap, Disclosure, Inflate Sales , ContentID: 120252984

Case Documents
1   CLASS ACTION COMPLAINT
[ see first page and extracted highlights below  ] ItemID: 128785
27 pages
PDF
Total Documents: 1 document , 27 pages
Price: $ 19.95


IVESLCD01 KGI0001
 
 

 Forgot your password?


1 . CLASS ACTION COMPLAINT

EXTRACTED KEY WORDS
STOCK
REPORT
VIOLATIONS
ROYALTIES
INVESTORS
REVENUE
SALES
SHARES
FASB STATEMENT
ENTERPRISE
DEFENDANTS
ACT
BUSINESS
SCHERING-PLOUGH
PHARMACEUTICALS
SECURITIES
SHAREHOLDER
RECEIVABLES
ANALYSTS
MANAGEMENT
RESOURCES
DIRECTORS
RIBAPHARM
CONTROL
EXPECTATIONS
EPS
GAAP
DISCLOSURE
INFLATE SALES
        MILBERG          WEISS  BERSHAD
          HYNES  &  LERACH  LLP
        WILLIAM          S. LERACH  (68581
        DARREN  J. ROBBINS  (16859  4 )
        401  B  Street,  Suite  1700
        San Diego,  CA  92101
        Tele  hone:  619/231-1058
        619&31-7423        (fax)

        SCHIFFRIN         &  BARROWAY,            LLP                                           -
                                                                                               . .
        MARC  A.  TOPAZ                                                                            
  f
        Three  Bala  Plaza  East,  Suite  400                                                  .:-
        Bala  Cynwyd,  PA  19004
  7
        Tele  hone:  6 1 O/667-7706
        6 1 OA67-7056  (fax)
  E



  g     CAULEY,        GELLER,  BOWMAN
         &  COATES,  LLP
 1c  PAUL  J. GELLER
        One  Boca  Place,  Suite  421A
 11  2255  Glades  Road
        Boca  Raton,  FL  3343  1
12  Tele  hone:  56 l/750-3000
        56 l/%0-3364       (fax)
13  Attorneys  for  Plaintiff
14

15                                    UNITED  STATES  DISTRICT  COURT

16                                   CENTRAL  DI!STRICT  OF  CALIFORNIA

17                                            SOUTHERN  DIVISION

18  YVETTE  VEIDEMAN,  On Beha&&  C  )-&X2-7 12 GLT  (AN  x)
19  Herself  and  All  Others  Similarly                 .
        Situated,                                              CLASS  ACTION
20
                                         Plaintiff,            COMPLAINT         FOR  VIOLATION    
21                                                             THE  SECURITIES       EXCHANGE
               vs.                                             ACT  OF  1934
22
        [CN  PHARMACEUTICALS,                  INC.,
23      MILAN  PANIC,  RICHARD  A.  MEIER
SNIPPETS:
  • ICN Pharmaceuticals, Inc. between 5/3/01 and 7/10/02
  • L for violations of the federal securities laws.
  • ICN is a researcht prescription and non-prescription pharmaceuticals.
  • ICN's common stock is traded on
  • Defendants reported favorable, but false
  • 14 .nflated stock price, certain of the defendants were able to sell 236,833 shares of their
  • 21 Sllass Period quarters to inflate sales.
  • 22 CN shareholder value, compared to the end of 2001.
  • 25 3xchange Act of 1934 and Rule lob-5.
  • ICN is headquartered in Costa Mesa, California, and conducts business
  • 13 Panic's diligence in developing Ribapharm.
  • 11 to nearly $50 per share as investors were led to expect strong results.
  • 16 shareholders to elect an independent board of directors.
  • While royalties are always a lower amount than
  • Schering-Plough later informed the Company that it believed royalties paid
  • 17 losition where a substantial part of its royalties revenue was at risk.
  • $0.34 in the same period of 2000, above analyst consensus expectations.
  • 14 recognition of millions of dollars in royalties it claimed were due from Schering17
  • analysts issued reports about ICN.
  • 18 Company a Buy, forecast EPS of $11.40 and $2.15 for 2001 and 2002, respectively,
  • CIBC World Markets Corp. issued a report initiating 4 coverage on ICN by Matt Geller.
  • IBecause this was Geller's first report on ICN, he r; J spent time talking to management to
  • Since Panic still had effecttive control of the board of ICN,
  • with GAAP are presumed to be misleading and inaccurate,
  • include disclosure which would be duplicative of disclosures accompanying annual
  • GAAP, as set forth in FASB Statement of Concepts No. 2,163, states in part:
  • about the economic resources of an enterprise, the claims to those resources, and
  • 10 Ibout how management of an enterprise has discharged its stewardship responsibility
  •    |